Compare Organon & Co. Common Stock (OGN) vs Invesco S&P 500 Momentum ETF (SPMO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Invesco S&P 500 Momentum ETF — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Invesco S&P 500 Momentum ETF trades at $143.87 (market cap $23.04B). The key difference: Invesco S&P 500 Momentum ETF is far larger — about 6.4× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Invesco S&P 500 Momentum ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Invesco S&P 500 Momentum ETF for 55 Days on average.
| OGN | SPMO | |
|---|---|---|
Market Cap | $3.62B | $23.04B |
Volume | 2,892,999 | 2,008,654 |
Sector | Health | Broad Market / Factor |
52-Week High | $13.81 | $161.66 |
52-Week Low | $5.70 | $107.84 |
Typical Hold Time | 0 Days | 55 Days |
Enterprise Value | $11.04B | — |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
SPMO, the Invesco S&P 500 Momentum ETF, trades at $148.03, down 0.89% on the day amid a bearish technical signal. The ETF recently completed its semi-annual reconstitution, adding 54 stocks including Apple and Merck while removing Nvidia. Its momentum strategy has historically outperformed the S&P 500 but faces near-term volatility from concentrated sector exposure.
Outlook remains mixed with strong long-term momentum performance offset by current technical weakness. Investment opportunity lies in capturing S&P 500's fastest-rising stocks, though risks include high volatility and sector concentration. The ETF's structural edge suggests potential for continued outperformance despite recent underperformance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Invesco S&P 500 Momentum ETF
SPMO is designed to track the investment results of the S&P 500 Momentum Index. This index measures the performance of stocks in the S&P 500 that exhibit the highest momentum, or the greatest price appreciation, over the trailing 12 months, while excluding the most recent month. By investing in these high-momentum stocks, SPMO seeks to capitalize on the historical trend that stocks with strong recent performance tend to continue that performance in the near term, offering a systematic approach to factor investing within the large-cap U.S. equity market.
Read more on SPMO →
